AVAX Technologies Inc

AVAX Technologies, Inc. is a biotechnology company based in Philadelphia, Pennsylvania. The company employs six people and generates annual revenue of $0.75 million. AVAX Technologies specializes in developing and commercializing its AC Vaccine® technology, a platform designed for the treatment of cancer. This technology focuses on creating personalized cancer vaccines, a complex and unique approach in the field of immuno-oncology. AVAX Technologies distinguishes itself through its advanced stage of development and commercial readiness within the immuno-oncology sector. The company operates a GMP approved facility, one of the few globally capable of producing autologous vaccine products. For more information about AVAX Technologies and its innovative cancer vaccine technology, please visit www.avax-tech.com.